Podcasts about cme

Send us Fan MailIf I walked into your organization today and asked you one simple question — “What is your revenue cycle trying to tell you?” — would you know the answer?Not your collections rate. Not your days in A/R. Not your monthly deposits. I mean the deeper answer. What operational stories are hiding inside your numbers right now?Because most healthcare organizations still think about revenue cycle as a billing department function. Claims go out. Payments come in. Denials get worked. Aging gets reviewed. End of story.But high-performing organizations understand something very different: your revenue cycle is not just billing. It is operational intelligence. It is one of the clearest mirrors of how your organization is actually functioning.Every metric tells a story. Your denial patterns tell stories. Your charge lag tells stories. Your payer behavior tells stories. Your provider coding and undercoding variation tells stories. Your scheduling data tells stories. Even your unapplied credits and unpostables tell stories. And the organizations that thrive financially are usually the organizations that have learned how to listen carefully.So today I want to challenge you to think differently about your revenue cycle. Not as a back-office function. Not as an administrative burden. But as one of the most important diagnostic tools in your entire organization.Because here's the truth: your revenue cycle is talking to you every single day. The question is whether anyone is listening.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/    

In this episode, Farm4Profit sits down with Tommy Grisafi, founder of Ag Bull Trading and Ag Bull Media, a veteran commodity trader with more than three decades of experience navigating agricultural markets. Tommy shares the story of how a high school field trip to the Chicago Board of Trade sparked a lifelong passion for commodity trading and eventually led him to become a member of both the Chicago Board of Trade and CME. The conversation explores the realities of grain marketing and why it often proves more difficult than growing the crop itself. Tommy dives into the emotions that drive decision-making—greed, hope, ego, and fear—and explains how these factors can quietly cost farmers more than any market downturn. Topics include: Tommy's journey from the CBOT trading floor to Ag Bull Trading How commodity markets have evolved over the past 30 years Whether today's flood of information helps or hurts decision-making How producers can identify trustworthy market advisors Why risk management matters more than ever The traits shared by successful grain marketers Common habits that hold producers back Why profitable opportunities are often missed Market outlooks for corn, soybeans, wheat, fertilizer, fuel, and interest rates What younger farmers should focus on as they build their operations The importance of discipline and consistency in marketing plans Tommy also shares stories from some of the most volatile periods in agricultural markets and discusses the lessons he's learned from both winning and losing trades. Whether you're marketing old crop grain, planning for next year, or simply trying to make better decisions in an uncertain environment, this episode offers valuable insights from someone who has spent a lifetime studying market behavior. Want Farm4Profit Merch? Custom order your favorite items today!https://farmfocused.com/farm-4profit/ Don't forget to like the podcast on all platforms and leave a review where ever you listen! Website: www.Farm4Profit.comShareable episode link: https://intro-to-farm4profit.simplecast.comEmail address: Farm4profitllc@gmail.comCall/Text: 515.207.9640Subscribe to YouTube: https://www.youtube.com/channel/UCSR8c1BrCjNDDI_Acku5XqwFollow us on TikTok: https://www.tiktok.com/@farm4profitllc Connect with us on Facebook: https://www.facebook.com/Farm4ProfitLLC/Farm4Profit Media is not a financial, legal, or tax advisor. Content is provided for informational purposes only, and we serve solely as a platform for third-party opinions. Any actions taken based on this content are at your own risk. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this special Bowel Sounds and Nutrition Pearls collaboration episode, hosts Dr. Jennifer Lee and clinical dietitian Nicole Misner talk to Lisa Richardson about the ins and outs of infant formula. This is a must listen episode for all pediatricians, pediatric gastroenterologists, dietitians and anyone who is using or recommending infant formulas. Learning ObjectivesExplain infant formula nutrition, components, and comparison to breast milkDifferentiate formula types, ingredients, and clinical useApply guidance for fomula selection, safety, and caregiver educationLinks:Infant Formula Preparation and Storage | Infant and Toddler Nutrition | CDCInfant Formula Homepage | FDAOperation Stork Speed | FDAInfant Formula ReferencesLarson-Nath C, Bashir A, Herdes RE, et al. Term infant formula macronutrient composition: An update for clinicians. J Pediatr Gastroenterol Nutr. 2025;80(5):751-759. doi:10.1002/jpn3.70002Rodrigo ML, Tymann HA, Lochen HA, Shores DR. Infant formula ingredients: Updates for clinicians. J Pediatr Gastroenterol Nutr. 2024;78(5):1005-1008. doi:10.1002/jpn3.12192Lewis JI, Dror DK, Hampel D, et al. Reference Values for Macronutrients in Human Milk: the Mothers, Infants and Lactation Quality (MILQ) Study. Adv Nutr. 2025;16 Suppl 1(Suppl 1):10050. doi:10.1016/j.advnut.2025.100501Taylor SN, Buck CO. Post-discharge nutrition to optimize preterm infant short- and long-term outcomes. Semin Fetal Neonatal Med. 2025;30(2):101637. doi:10.1016/j.siny.2025.101637Send us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Crain's healthcare reporter Jon Asplund joins host Amy Guth to discuss West Suburban Medical Center's second forced closure this year and federal prosecutors dropping charges in the $300 million Loretto Hospital fraud case. Plus: Huntington Bank expands office footprint, bucking Loop downsizing trend; distressed Gold Coast hotel goes up for sale; CFTC considers blocking CME's 24/7 oil contract bid; and how the FAA's O'Hare flight cuts could affect your summer travel. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications

Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics: Introduction (0:00) Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05) Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21) Chimeric Antigen Receptor (CAR) T-Cell Therapy for DLBCL — Dr Kamdar (43:12) CAR T-Cell Therapy for Follicular Lymphoma (FL) — Prof Salles (1:08:33) Other Approved and Emerging Novel Therapies for FL — Dr Patel (1:24:44) Integrating Bispecific Antibodies into the Management of FL — Dr Kamdar (1:41:34) CME information and select publications

In this episode Amanda and I discuss Michael Saylor's Strategy Bitcoin lie, Jim Cramer SpaceX IPO vs Bitcoin, MasterCard AI Agent stablecoin payments, CME crypto index futures, new legislation to establish the Federal Cryptocurrency Theft Task Force, and much more.Brought to you by

Featuring perspectives from Dr Thomas E Hutson, Dr Erik A Singer and Dr Ulka Vaishampayan, moderated by Dr Hutson, including the following topics: Introduction (0:00) Current Indications for Adjuvant Immune Checkpoint Inhibitor Therapy in the Management of Renal Cell Carcinoma (RCC) — Dr Singer (2:32) Potential Role of Hypoxia-Inducible Factor-2 Alpha Inhibitors as a Component of Adjuvant Treatment — Dr Hutson (30:53) Tolerability of Current and Emerging Adjuvant Approaches for RCC — Dr Vaishampayan (1:06:37) CME information and select publications

The Obama Presidential Center was meant to lift up local contractors. Some say they're paying a high price for the project's delays and cost overruns. Crain's commercial real estate reporter Danny Ecker talks with host Amy Guth about how some contractors say they're fighting to collect millions of dollars in unpaid bills. Plus: Illinois joins states' challenge to Trump's anti-DEI contract rules, CME plans to offer 24/7 oil and gold contracts, Prada's Oak Street flagship building up for sale and Chicago gets one more shot at fixing the parking-meter mess. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

BEEF We'll start again with the New World screwworm. We now have 6 confirmed cases in Texas and 1 in New Mexico. Affected animals are a dog, a goat and 5 cattle. While our border with Mexico has been closed for months now to live animals, Texas cattle is now barred from export to Canada and I'd expect that list to continue to grow. This is a growing issue that will affect our beef industry for the foreseeable future. Beef production was 533K head last week, up from the holiday shortened prior week of 448K. This keeps inventories tight and product prices pushing higher. Middle meats, those ribeyes, tenderloins, and strips are finding support to continue moving higher. Chucks and rounds are holding steady for now though they are not big demand items in the summer. Ground beef is the big demand item and it's moving higher every day. Briskets and sirloin flap are moving lower, but I don't think we'll see this for long. It's a market where I'd make sure I stay ahead of my needs and keep inventory on hand. This market is moving higher.  POULTRY The declining chicken market is done. Pricing will be moving higher next week on boneless skinless random breasts, tenders and party wings. Compared to other proteins, still a great value but the declines of the last month are done. Chicken production continues strong up about 2% over last year. There is plenty of chicken in production. On the avian flu report, only three new cases affecting 20K birds. The summer is looking good for avian flu. GRAINS Corn continues to be a great value closing at $4.25/bushel today, that's down from $4.39 last week. Soy has pulled back a bit from the highs we saw last week, but I would not be surprised if they go on another run. High fuel prices put soy in play with biofuels, that is not over. Wheat is moving lower; I do think we'll see lower flour costs soon. PORK Pork bellies holding steady for the week, closing today at $120, about the same as last week. This will be moving higher soon, but it is a great price right now. Butts were on a tear higher, but they seem to have leveled off, we may see some better pricing shortly. Ribs are about as high as expected to see them this year. Loins continue to be the value in pork.  DAIRY CME Limited moves on the CME this week, thru Thursday's close, butter is down 2, block is up 1, and barrel is up 2. Let's look for a quiet market at least the next couple weeks. Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

Fabrice Bernhard is the co‑founder and Chief Technology Officer of Theodo Group, a global technology consulting firm he co‑founded in Paris in 2009. Under his technical leadership, Theodo has grown rapidly by combining Lean principles with modern software engineering to help organizations build scalable, resilient digital capabilities. Fabrice is a recognized thought leader in Lean Tech, advocating for the application of Toyota Production System principles to software development and technology organizations. He is a frequent speaker and writer on continuous improvement, learning cultures, and human‑centered technology, and is a co‑author of The Lean Tech Manifesto. His work focuses on enabling teams to deliver value faster while empowering people through better systems and smarter use of technology.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA). For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Featuring perspectives from Dr Sara A Hurvitz and Dr Virginia Kaklamani, including the following topics: Introduction: Which Biomarkers and When (0:00) Optimizing First-Line Therapy for Patients with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) (5:31) SERENA-6 Trial (19:44) Inavolisib (23:08) Management of HR-Positive mBC Progressing on a CDK4/6 Inhibitor and Endocrine Therapy (31:46) Selective Estrogen Receptor Degraders (41:15) AKT (46:13) CME information and select publications

Listen to the SF Daily podcast for today, June 11, 2026, with host Lorrie Boyer. These quick and informative episodes cover the commodity markets, weather, and the big things happening in agriculture each morning. The USDA's June WASDA report release today is expected minor demand adjustments, and Brazil's Conab updated crop estimates. Weekly export sales data showed steady ethanol production at 1.108 million barrels per day, with Midwest output rising. Live cattle futures gained 42 cents to $207, while feeder cattle futures were mixed. Mexico suspended U.S. cattle imports due to screw worms. Severe weather in the Midwest included tornado warnings and flash flood risks. The CME feeder cattle index dropped to $360.806, and wholesale box beef prices varied. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Social determinants of health, including housing, food access, insurance status, and structural inequities, significantly influence stroke prevention, recovery, and long term outcomes. These factors affect biological risk, treatment adherence, and disparities in care, even when traditional clinical measures are addressed. This episode highlights practical strategies for integrating screening, leveraging multidisciplinary teams, and identifying opportunities for advocacy to improve patient outcomes. In this episode, Teshamae Monteith, MD, FAAN, speaks with Nneka L. Ifejika, MD, MPH, author of the article "Social Determinants of Health and Their Impacts on Stroke Prevention and Outcomes" in the Continuum® June 2026 Cerebrovascular Disease issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Ifejika is an adjunct professor of physical medicine and rehabilitation at UT Southwestern Medical Center in Dallas, Texas, and the chief scientific officer of the Division of Academics at Ochsner Health System in New Orleans, Louisiana. Additional Resources Read the article: Social Determinants of Health and Their Impacts on Stroke Prevention and Outcomes Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Full episode transcript available here Dr Monteith: Two patients have the same stroke, but when they return, they have very different outcomes. We can look into some of their comorbidities, but something we don't spend enough time talking about is the social determinants of health. Stay tuned to this discussion. I promise you, you'll become a better neurologist. Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Monteith: This is Dr. Teshamae Monteith. Today I'm interviewing Dr. Nneka Ifejika about her article on social determinants of health and their impacts on stroke prevention and outcomes. This article appears in the June 2026 Continuum issue on cerebrovascular disease. How are you? Welcome to our podcast. Dr Ifejika: Thanks for having me. I'm doing great. Dr Monteith: Great. So, can you introduce yourself to our audience? Dr Ifejika: Sure. I'm Dr. Nneka Ifejika. I am the Chief Scientific Officer of Ochsner Health System in New Orleans, Louisiana. But I'm also a cerebrovascular rehabilitation doctor. I've been practicing for about nineteen years, and am happy and honored to be a contributor to this Continuum Neurology article. It's a really important topic. Dr Monteith: Great. So, what got you into this field, first of all? Dr Ifejika: Well, I was deciding between PM&R and neurology, and I was putting in both match lists. And I thought about it and I leaned toward PM&R, but stroke still had a grasp on my heart and my mind. And so, after I finished my residency, I joined the UT Houston stroke team, and I did a, thankfully did a two-year fellowship and became cross-trained in stroke as well as physical medicine rehab. So, I am a jack of both trades. Dr Monteith: So, you got your way in a way. Dr Ifejika: I did. Dr Monteith: You know, we have a lot of learners that are listening, so it's always, uh, nice for them to be inspired, I think, by people's career paths. So why don't we talk about the objectives of your article? Dr Ifejika: Sure. So, one of the most important things that we wanted to do was make sure that medical students, residents, faculty, and fellows understood the impact of social determinants of health on stroke recovery and stroke rehabilitation. It's not as simple as you have hypertension, hyperlipidemia, we're going to manage your stroke risk factors. Oh, you had an ischemic stroke. You presented in time for the window. We're going to give you endovascular therapy and then modified Rankin scale at hospital discharge in ninety days. No, no, no. The stroke survivor and their caregivers and their family have a lot more to deal with outside of what we look at during the acute stroke hospitalization and post-acute rehabilitation. Things like, can they afford the medication that we're prescribing? Antiplatelet agents or anticoagulation can be extremely expensive. Do they have housing insecurity? Is there food insecurity? What's going on behind the scenes that we are not addressing that can directly impact the admission rate and the readmission rate after we take care of a stroke survivor? Dr Monteith: I love the article because you took a real deep dive into social determinants of health, what they are, why they matter, and what we can do about them. And so why don't we talk a little bit about the NINDS framework for social determinants of health? I think many of us might not be familiar with the framework per se. Dr Ifejika: So, the framework consists of multiple domains specifically that relate to social determinants of health that were published in Neurology a couple of years ago. So, I do hope that people who are hearing this recording actually read them. There are interpersonal domains, there are classic medical domains, there are indeterminate domains, and there are six total domains. And health domains are the last domain. So, things like when it comes to housing insecurity, food insecurity, that's a domain of social determinants of health. When it comes to chronic racism, when it comes to biases that patients experience, those actually impact outcomes. So, there are six separate indices that we're going to get into in detail and how we address them as clinicians, whether it be at the medical student level, resident level, faculty level, to integrate the social determinants of health in our care plans, because we could be doing a much better job. And I think it'll be really important from the interpersonal perspective when we really relate to our patients and their families that we ask these questions. For example, if we're prescribing someone to have treatment for their diabetes mellitus and ha- and, and be taking insulin, if they have housing insecurity and they're in a homeless shelter, they have to leave the homeless shelter during the day. So, what happens to the insulin that we prescribe? These are variables that we are not considering on a regular basis, but they directly relate to compliance. Dr Monteith: Great. So that was one thing I wanted to bring up. We're very good at measuring blood pressure and trying to determine, uh, the association between stroke outcomes and things that we can measure, glucose, lipids, blood pressure. What is the evidence for social determinants of health and stroke outcome? Dr Ifejika: The evidence is growing, and there have been many publications that have come out that are, are going to be highlighted in this article related to structural determinants of health inequities, like structural racism, as well as disparities related to ethnicity and race. There's geographical disparities. For example, a lot of patients are, are primarily concerned about rural versus urban, whether you have access to different post-acute rehabilitation, whether you have access to secondary stroke prevention because you simply don't have the transportation from a, a rural area to get to a drugstore to get things available to you. Social status. There are actually publication related to socioeconomic status and the concerns when it comes to air pollution. So particulate matter 2.5, we know that that has a direct impact on stroke outcomes and health overall, but we don't really think about it as a structural determinant of health inequity. There's several multiple layers of research that have gone on specifically that have been cited in the literature that relate directly to social determinants of health and how we can address them moving forward. Dr Monteith: And what I found interesting in your article in that you gave at least a few examples where social factors like income, education were controlled for, and maybe in large part it is, but even when you control for some of these very obvious social risk factors, you still have inequities. Dr Ifejika: Absolutely. And I think it was really important to show that we had strong peer review evidence behind this, as it wasn't just something that we were creating or hypothesizing about. There have been studies that have been done over this over decades of time, showing the impacts of social determinants of health on outcomes. But the question and concern that we have is we know this growing body of literature continues to expand. What are we doing about it when it comes to education of the future generations of providers who will be caring for this population? Dr Monteith: Before we get into how, you know, what we're going to do about that, let's just kind of put that link, cause the evidence is there. How does it drive biology? Dr Ifejika: It's a great question. So, for example, particulate matter 2.5 in air pollution has been shown to have an existing impact on hypertension, raising your blood pressure. So that's a direct effect of a social determinant of health related to socioeconomic status because people who live in areas with higher air pollution are... They're not green spaces. They live near highways. Those are areas that unfortunately are also impacted by food deserts. Food deserts, if you're not able to get fresh fruits, vegetables, whole foods, increases your risk of developing diabetes, hyperlipidemia, also increases your sodium intake, again, increasing hypertension. These things are all connected to biological determinants. It's just that we're not asking about them necessarily within the social history when we're taking people into the hospital, but they have direct effects. Dr Monteith: Great. Neurologists tend to be busy and, you know, we're... have all of these things that we're being asked to do and chart and click and all of that stuff. And so how can we more readily integrate screening for social determinants of health and that conversation into the work we do? We recognize it's important. We recognize it's an important risk factor. There's a lot of these determinants. So, what is a good way to do so? And I, I know that in the paper you've, you've given different roles to different team players, so I want you to talk about that too, but just kind of even a regular routine office visit. Walk us through a way we can more easily integrate that kind of conversation. Dr Ifejika: It's an excellent question, and what I've recommended that we do in a standard office visit is utilize the time before the visit to send out screeners. So, for example, usually with an electronic medical record, you can send documents before the visit even starts, where people can check off whether they have any concerns regarding housing, food insecurity. They can check out their location of where they live, whether they live near a highway or not near a highway. It's specifically related to socioeconomic status. We can ask about insurance status, whether they have insurance, insured versus uninsured, but then also types of insurance, whether they have Medicaid insurance versus Medicare insurance. Then even drilling even further, type of Medicare insurance, Medicare Advantage versus traditional Medicare, cause all of those things actually play a role in this. Dr Ifejika: And evaluate these things and don't take time during your office visit. Send these screeners out beforehand. Have them be assimilated by your medical staff. Make sure you're utilizing every resource that you have at your disposal to help streamline things, so by the time the person comes in for the visit, you've primed the pump. You have this information already in your hands at your fingertips cause it was sent out in advance, and you have your medical staff already have an understanding of. If they didn't fill it out electronically, give it to them in the lobby. Make sure they have a handwritten copy in the lobby so that when they come into the office visit, you have the information at your fingertips. Dr Monteith: Are there any particular resources that you recommend for those types of screeners? Dr Ifejika: What I've used in the past, if you have patient-reported outcomes, so the PROMIS instruments, that's a good start. It doesn't get into the details of housing insecurity, food insecurity, but it's a good start to help prime questions and to start the conversation during your office visit. In my clinics, I do a PROMIS 27 on every patient, as well as a PHQ-9 for depression on everyone. And then I collect data longitudinally, and I can always drill down on factors that I noticed that could become a problem moving forward. Dr Monteith: Yeah. And then also in your article, you spoke a bit about this impact from the acute presentation in the hospital to rehab. Dr Ifejika: Yeah. Dr Monteith: So why don't you talk about these different entry points where we can really engage our patients and try and help reduce their burden? Dr Ifejika: Sure. So, healthcare can be quite fragmented, and the stroke patient, stroke survivor, and their family member have no grasp of that. They've had a stroke, and they may be going from the ER to the ICU to the stroke unit to the floor to the rehab unit, and we see it as multiple levels of care, multiple types of providers. They see it as one hospital. And the concern that we have is, at those branch points, things get dropped, and we have the opportunity to pick things up at those branch points. So, during the acute care hospitalization-Primarily, that's the establishment of what has happened, how we're gonna treat it, what are the variables that we can control for right now to address those determinants of health moving forward, and to specifically looking at whether they were taking medications before, whether they could afford medications before, what that looks like at hospital discharge. Is there any duplication of medications? If a person is taking Coreg and you prescribe metoprolol, but they still have the Coreg at home, should we have really prescribed the metoprolol? We're just spending money that they may have concerns when it comes to access to care and the cost of these prescriptions. So, it's the responsibility of the acute care physician to kind of look at that. Those are subtle things that we think are subtle, but they add up quickly for the family when it comes to having one group of medications that's the same class and having to buy another type. When it comes to post-acute rehabilitation, it's really an important time to screen for whether the caregiver can handle what's occurring. So specifically, if the caregiver is already burning out and the average length of stay for a stroke patient is five days and they've come to rehab for two weeks, what's gonna happen in the next two years or the next four years? So, during the post-acute rehabilitation phase, it's time to kind of look at that and drill down on those kind of questions. Also, the levels of care, Dr Ifejika: it's really important to look at other levels of rehabilitation, so skilled nursing facilities, making sure people have access to that if they need to, if the caregiver is burned out and they don't have the ability to go straight home. Because acute inpatient rehab, the goal of it afterwards, is to go straight home. It's not to go to another facility. So, you need to have that screener in place when it comes to whether the family can take care of this person, and whether the family can do it in an effective way to prevent them being readmitted. Dr Monteith: Great. I also like that you spoke about kind of the team approach and different roles, both for screening and for intervention, both being very important, especially the intervention. And so why don't you give us a few examples how the team could break up the responsibility and how also for the intervention component that can be done. Dr Ifejika: Sure. So, I broke up the team into several levels. So, the team medically is the medical student, resident, and faculty physician. However, the team also includes the support staff, so your case manager, your social worker, the therapist, physical therapy, occupational therapy, speech therapy, the pastoral services, all these members of the team. You know, sometimes as physicians, we don't read those notes. There's a lot of information in the notes from social work, care coordination, and the therapist. They get down to subtleties cause they're asking questions, for example, "What kind of equipment do you have at home? How many stairs do you have at home? What level of house do you have, one story, two story? If you live in an apartment, do you have an elevator access?" That's important for someone with hemiparesis. When it comes to medications, when it comes to insurance status, when it comes to your ability to have the mechanisms to pay for care as an outpatient, social workers are required to ask these questions cause they have to figure out resources for the patient and their family to help facilitate improved outcomes. So, they have to ask questions regarding these tasks. The concerns are, do we read what they're saying? So, it's really important to interact with them, and if it's not something that you're looking at in the chart, cause we're all so tied to our computers, find where they are in the hospital. Walk by their office and have a chat. Run your list with them, especially for people who you're concerned have vulnerabilities, and make sure that you're setting an example for your medical students with your faculty doing so. If you're looking at it from the medical student, resident, faculty perspective, medical students, listen. This is your opportunity to really contribute to the team as well as learn about social determinants of health and research in their fields. You are the boots on the ground for the medical team. You are the ones who should be priming the pump and asking these questions of the family members. We're sending you into the rooms to do a history and physical. Social determinants of health should be a part of your history and physical, and you should be taking what we're saying in this article and asking these questions and tying it into your resident. Now, the resident is the work person of the hospital. We all know this. Things run through the resident. Things run through the fellow. It's really important that they have this information in a manner that is negotiable. The list keeps getting longer, and a resident doesn't need to be overburdened. It needs to be synthesized in a manner that can help facilitate the resident being able to act as well as communicate any concerns to the faculty. And at the faculty level, we are the voices that can affect change. So, if there's any concerns when it comes to advocacy, research, making sure that people are accessing care in a way that makes sense, particularly when it comes to the ability for us to galvanize change on a national level, that's kind of our job. Dr Monteith: Great, and so let's talk about intervention. What are things that, let's say, the neurologist can do to deal with some of these social factors? Dr Ifejika: From the neurology perspective, I think it's really important to identify missed opportunities and making sure that we address them. For example, the conversations around the ability to have access to care related to insurance versus no insurance. There are many, many ways that neurologists are able to advocate for a person being able to get to Medicare insurance, particularly in the outpatient setting. When we see patients in clinic, it takes two years, them, to qualify for Medicare, two years at a minimum. But there's a gap there that can be filled by us making sure that we document what's happened, contact their providers, facilitate communication with their employers, if they're employees, they can get some short-term disability benefits to help bridge that gap prior to receiving Medicare insurance. It behooves us to do this because if we do not, they fall into the gap and they get readmitted and they're back on service anyway. So, what's important is the outpatient that we really kind of focus on things that we can impact and things like insurance and getting people transitioned from having employer-based insurance versus getting to Medicare is a really important way that we can effect change in a, in a way that's viable and, and replicable. So, in the outpatient setting, neurologists have a wonderful opportunity to effect change in social determinants of health. When it comes to employed persons, who had a stroke transitioning to Medicare, it takes two years to do so. So, in the outpatient clinic, if you have an employed person, make sure that you fill out their short-term disability benefits forms, their long-term disability benefits form. Bridge the gap. Get that information to their employer so they can maintain constant coverage. Because if they do not, if they have to choose between refilling medications and putting food on the table, they're going to choose putting food on the table, and that's going to directly impact their outcomes if they're not taking the medication that we recommend. Dr Monteith: I think that's a great point. I mean, there's a lot that we can do, and in some ways, it may not take that much to document and to be able to ask the questions and to include some of that information into the assessment and plan is really a, a great idea. Dr Ifejika: And you know, if we don't bring these things up and have these conversations, it doesn't get addressed. And that's why I'm very, very thankful that I had the opportunity to do so, cause this is a part of what I do all day. I think that if I wasn't integrating these kind of conversations into my practice, I wouldn't have the ability to share these tips and these abilities to move things forward in a manner that will be constructive for our field overall and for our patients. Dr Monteith: And towards the end of the article, you brought up something I think we don't see in many articles, and that's the role of advocacy and getting involved in health policy. So, can you talk a little bit about that? Dr Ifejika: You know, it's really important to facilitate change when you see that there are things that need to be changed. And the best way to do that is through advocacy at the local or state or federal level. A lot of these variables that we're dealing with can be addressed through legal changes. I'll give you an example. End-stage renal disease, if you have immediate hemodialysis and you have that requirement upon hospital discharge, you qualify for Medicare immediately. Immediately. Before you even leave the hospital. Why wouldn't something be similar for a stroke? Well, the reason why is because there was a level of advocacy that came around end-stage renal disease and a member of Congress's wife had hemodialysis requirements. And so, a law was passed to make sure Medicare covered it immediately after hospital discharge. So, it requires advocacy in some significant ways to get things done, but we have the bandwidth to do this. We take care of a population that has some of the highest rates of preventable disability. That's not going away. We need to make sure that we're effecting change for this group to make sure that they have the best possible outcomes they can experience. Dr Monteith: So, any final messages for our listeners? Dr Ifejika: I look forward to hearing everyone's feedback about our issue. I am thankful for the opportunity to talk about, address, and write about this important topic, and look forward to everyone's feedback. Dr Monteith: Well, thank you so much for being on our podcast. It was a really wonderful summary and we had a very thorough conversation, but you didn't give away too much, so I think they're going to have to read the article. Dr Ifejika: You're going to have to read the article. And we want medical students, residents, fellows, faculty, all of our ancillary staff within the hospitals, please read this article. We really appreciate it. Dr Monteith: Again today, I've been interviewing Dr. Nneka Ifejika about her article on social determinants of health and their impacts on stroke prevention and outcomes. This article appears in the June 2026 Continuum issue on cerebrovascular disease. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Let Babies Eat: New Guidelines to Prevent Food Allergies FACULTY: David Stukus, MD is a Professor of Clinical Pediatrics and the Director of the Food Allergy Treatment Center at Nationwide Children's Hospital and the Ohio State University College of Medicine.   OVERVIEW: In this grand rounds episode of Pediatrics Now, host Holly Wayment brings us cutting-edge approaches to infant food introduction and allergy prevention, featuring Nationwide Children's Hospital's Dr. David Stukus .   Dr. Stukus delves into the history of infant feeding guidelines, the evolving scientific evidence, and practical strategies for pediatric practitioners. Listeners will gain insights into the confusion caused by changing guidelines, the landmark LEAP trial's impact on peanut allergy prevention, and the importance of introducing allergenic foods early, based on evidence rather than outdated practices. The episode provides evidence-based recommendations to support parents, addressing common misconceptions and fears about food allergies.   Join the discussion to better understand the relationship between eczema and food allergies, how to effectively reassure and guide families during clinics, and strategies to help pediatric patients achieve diverse diets that minimize allergy risks. Learn how pediatricians play a crucial role in educating families and preventing unnecessary dietary restrictions that can lead to food allergies. This episode is a must-listen for any healthcare professional looking to navigate the complexities of infant nutrition and allergy prevention with clarity and confidence.   OVERALL LEARNING OBJECTIVE: Increased awareness and education for pediatric providers DISCLOSURE TO LEARNERS: David Stukus, MD has disclosed he is a researcher for DBV Technologies and was a consultant to ARS Pharmaceutical and Genentech. The relevant financial relationships noted for Dr. Stukus have been mitigated.   The Pediatric Grand Rounds Planning Committee (Deepak Kamat, MD, PhD, Steven Seidner, MD, Daniel Ranch, MD and Elizabeth Hanson, MD) has no financial relationships with ineligible companies to disclose. The UT Health Science Center San Antonio and Deepak Kamat, MD course director and content reviewer for the activity, have reviewed all financial disclosure information for all speakers, facilitators, and planning committee members; and determined and resolved all conflicts of interests. CONTINUING MEDICAL EDUCATION STATEMENTS: The UT Health Science Center San Antonio is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The UT Health Science Center San Antonio designates this live activity up to a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the activity, with individual assessments of the participant and feedback to the participant, enables the participant to earn 0.75 MOC point in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit. CERTIFICATE OF ATTENDANCE: Healthcare professionals will receive a certificate of attendance and are asked to consult with their licensing board for information on applicability and acceptance. Credit may be obtained upon successful completion of the activity's evaluation. RELEASE DATE: 2/5/2025 EXPIRATION DATE: 8/31/2027        

Featuring perspectives from Dr Christine L Hann and Dr Jacob Sands, including the following topics: Introduction: Biopharmacology of Small Cell Lung Cancer — "Wildfire sparked in dry grass" (0:00) Limited-Stage Disease (9:22) Extensive-Stage Disease (16:23) Paraneoplastic Syndromes — Lambert-Eaton Myasthenic Syndrome (23:54) Bispecific T-Cell Engagers — Tarlatamab (30:00) Antibody-Drug Conjugates — Ifinatamab Deruxtecan (39:19) Other Novel Agents — Alisertib, Chimeric Antigen Receptor T-Cell Therapy (52:54) CME information and select publications

Send us Fan MailLast week, we talked about some of the biggest differences between struggling medical groups and high-performing organizations. We discussed long-term thinking, strategic staffing, operational intelligence, investment philosophy, and diversified revenue streams.And today, we're continuing that conversation — because once organizations begin growing successfully, entirely new challenges emerge. Growth sounds exciting. But growth without infrastructure creates chaos very quickly. And high-performing organizations understand that scaling successfully requires discipline.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/    

 In this episode, we will focus on the latest in the research on ALS. ALS remains a devastating disease, but the field is now at an inflection point with a growing pipeline of precision therapies, trial-ready sites, and a new generation of clinician scientists - yet barriers persist. There is disease heterogeneity, limited trial access for patients, and rising development costs. For an update on ALS clinical trials and the Healey ALS MyMatch program, a centralized platform that matches participants to trials, we spoke with Dr. Suma Babu. Dr. Suma Babu is an associate professor of neurology at Harvard Medical School and co-director of the Neurological Clinical Research Institute at Mass General Brigham. She was interviewed by Dr. Ryan Jacobson, an associate professor of neurology at Rush University.    Disclosure: This episode does not award CME.

Are academic medical conferences falling short when it comes to preparing clinicians for the unpredictable realities of modern surgery and patient care? In this episode of BackTable Industry, co-founder Anish Parikh interviews Dr. Ruchika Talwar about the real-world challenges traditional conferences often overlook and how informal, peer-to-peer exchanges like those at Creator Weekend™ in Nashville bridge the gap. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction02:37 - Why Conferences Miss It06:35 - From Training to Practice08:10 - On Call Reality Check10:39 - Learning With Videos14:44 - Keeping Up With New Info16:37 - Rise and Fall of Urology Twitter19:27 - Lifelong Learning and Patients25:44 - CME and Med Ed Revolution28:30 - Closing Thoughts --- More about this episode Together, they unpack what it really takes to bring new NMIBC therapies into clinical practice, from navigating approval barriers and staffing challenges to managing workflow and operational details. Dr. Talwar shares insights on moving from training to independent practice, navigating on-call emergencies with quick learning tools like surgical videos and residency notes, and building patient-centered approaches beyond rigid guidelines. The conversation also explores how surgeons use their own "game tape" to improve, the rise and fall of online medical communities like MedTwitter, and the evolving landscape of CME and lifelong learning for today's physicians. --- Resources Hinman's Atlas of Urologic Surgeryhttps://www.clinicalkey.com/#!/browse/book/3-s2.0-C20210026651 American Urologic Association Guidelines & Video Bankhttps://www.auanet.org/guidelines-and-quality/guidelines --- Backtable Industry is the go-to podcast for healthcare leaders, business-minded providers, and innovators that are shaping the future of healthcare. Download the free BackTable app to get early access to new episodes. ► https://www.backtable.com/app

Become the Medetomi-Dean of AdmissionsStep up your hospital addiction medicine game by learning to troubleshoot methadone dose confirmations/missed doses and understanding how medetomidine's emergency in the drug supply is impacting patients and withdrawal management. We're joined by Dr Maggie Lowenstein (University of Pennsylvania)Claim CME for this episode at curbsiders.vcuhealth.org!By listening to this episode and completing CME, this can be used to count towards the new DEA 8-hr requirement on substance use disorders education.Episodes | Subscribe | Spotify | iTunes | CurbsidersAddictionMed@gmail.com | CME!Credits Writer, Producer, and Show Notes: Shawn Cohen MD Infographic and Cover Art: Zoya Surani  Hosts: Carolyn Chan, MD. MHS and Shawn Cohen MD Reviewer: Payel Jhoom Roy MD, MSc Showrunner: Carolyn Chan, MD, MHS Technical Production: PodPaste Guest:  Maggie Lowenstein MD MPhil MSHP Sponsor: BabbelGo to Babbel.com/CURB for up to 60% off.Sponsor: FIGSCurbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.Sponsor: FreedSetup takes 30 minutes and pricing starts at $149 a month. Try it free for 7 days at getfreed.ai/front-desk.

Featuring perspectives from Prof Thomas Powles, including the following topics: Circulating tumor DNA (ctDNA) analyses with adjuvant nivolumab for MIBC in the CheckMate 274 study (0:00) Use of ctDNA to guide response-adapted bladder preservation for patients with MIBC (2:27) ctDNA response-adapted treatment de-escalation for patients with metastatic urothelial carcinoma: The CT-READ trial (10:26) Emerging data and studies regarding urinary tumor DNA (18:04) CME information and select publications

Dynamic Movement Intervention, Cuevas Medek Exercises and the state of the evidence. Challenging the status quo.

Graham Allcott is an author, speaker, and entrepreneur. He is the author of multiple books, including the global bestseller How to Be a Productivity Ninja, How to Have the Energy, and How to Fix Meetings. His latest book, KIND: The Quiet Power of Kindness at Work, focuses on why organisations with kinder, more human-centred cultures are ultimately more successful.He is the founder of Think Productive, which since 2009 has been a professional development go-to for a variety of companies, including Amazon, British Airways, Disney, eBay, the British Red Cross and many more – and with offices in the UK, USA, Canada, Australia, New Zealand, the UAE and the Netherlands.Earlier in his career, Graham was the co-founder of Intervol (an international student volunteering charity), the Chief Executive of Student Volunteering England, the Head of Volunteering at the University of Birmingham, and an advisor to the UK Government on youth volunteering policy.In his spare time, Graham is a DJ, with a leaning towards jazz, rare groove, and electronic music. Despite an intolerance of failure elsewhere in his life, he is an Aston Villa season ticket holder and an avid follower of the Toronto Blue Jays baseball team.Sign up for Graham's weekly email, "Rev Up for the Week" by visiting his website www.grahamallcott.com.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Blue Origin has a relly bad day. A cannibal CME could bring aurora to middle latitude regions. Cape Cod experienced a big boom. And NASA says goodbye to MAVEN. Become a supporter of this podcast: https://www.spreaker.com/podcast/made-of-stars--4746260/support.

Featuring perspectives from Prof Ramez Eskander and Dr Bradley Monk, moderated by Dr Kathleen Moore, including the following topics: Introduction (0:00) Advances in Human Cadherin-6-Targeted Antibody-Drug Conjugates (ADCs) in Ovarian and Other Gynecologic Cancers — Dr Moore (1:30) Leveraging TROP2-Directed ADCs in Advanced Gynecologic Cancers — Prof Eskander (35:39) Tolerability and Other Practical Considerations with Novel Investigational ADCs in Advanced Gynecologic Cancers — Dr Monk (1:04:58) CME information and select publications

Update Series (2026): Kidney Stones and the Infected Patient Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Mantu Gupta, MD Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== In this solo masterclass, John walks through the five steps he took to go from a family medicine physician to a hospital chief medical officer, and how to do so more intentionally than he did. It took him about 20 years. With the right approach, he believes it can be done in far less time. The five steps are straightforward:  Start volunteering in non-clinical hospital roles and say yes to opportunities, Find one or more mentors, Take on part-time medical director or physician advisor work while still practicing, Pursue formal business and management education, and Ask for the job.  John works through each using his own career as the example, including how chairing a hospital CME committee eventually led to a national accreditation role at the ACCME.  You'll find links mentioned in the episode at nonclinicalphysicians.com/path-to-hospital-executive/.

Brief Summary:Bitcoin fell below $70K this morning, trading near $69,400 after hitting a seven-week low area.Ethereum is holding near $1,975, still struggling around the $2,000 psychological level.About $744 million in crypto liquidations hit the market over 24 hours as leverage unwound during the selloff.Digital asset investment products saw $1.67 billion in outflows last week, the second-largest weekly withdrawal of 2026.Bitcoin funds posted their largest weekly outflow of the year, while XRP and HYPE were rare bright spots with inflows.Strategy's first disclosed Bitcoin sale continues weighing on sentiment, even though the company sold only 32 BTC worth about $2.5 million.Mt. Gox moved 10,306 BTC, worth about $739 million, to two addresses, creating fresh concern about potential supply pressure.CME's new 24/7 crypto derivatives market saw about $50 million in opening weekend trading.Robinhood closed its $180 million WonderFi acquisition, expanding its Canadian crypto footprint.Reuters reported a policy split on stablecoins, with the Bank of England more skeptical and Fed official Christopher Waller more supportive.Japan's ruling-party panel wants the country to promote yen stablecoins and create a legal framework for crypto ETFs.Vitalik Buterin proposed options-based synthetic assets to reduce DeFi liquidations and reliance on real-time oracles.Binance launched access to U.S. stocks and ETFs, pushing further into traditional brokerage territory.Dogecoin gained access to the Paxos network used by PayPal and Venmo.BitMine acquired 26,497 ETH despite weak Ethereum price action. Hosted on Acast. See acast.com/privacy for more information.

Interview conducted with Prof Bernd Kasper on March 5, 2026, by Dr Neil Love, including the following topics: Current management of desmoid tumors: A review from the Desmoid Tumor Working Group (0:00) Long-term nirogacestat treatment in adult patients with desmoid tumors: Updated efficacy and safety from the Phase III DeFi trial (8:26) Phase IV trial of nirogacestat in adult premenopausal women with desmoid tumors (17:35) CME information and select publications here.

Send us Fan MailWhy do some medical groups thrive while others constantly struggle — even in the same market?Have you ever looked at two practices in the same city, with similar physicians, similar patient populations, and similar payer contracts… and wondered why one group seems calm, strategic, financially healthy, and growing — while the other feels stressed, chaotic, reactive, and constantly fighting fires?That difference is rarely luck. High-performing medical groups think differently. They make decisions differently. They build systems differently. They lead differently. They invest differently. And perhaps most importantly, they understand that success in healthcare today requires far more than simply being clinically excellent.Because let's be honest — almost every physician group is working hard. That's not the differentiator anymore. The differentiator is operational intelligence. The differentiator is leadership. The differentiator is culture. The differentiator is the ability to think strategically instead of reactively.And today, we're going to talk about what high-performing medical groups actually do differently. Not from a theoretical textbook perspective. From the real-world trenches of healthcare operations. Because thriving organizations don't happen accidentally. They are built intentionally.Please Follow or Subscribe to get new episodes delivered to you as soon as they drop! Visit Jill's company, Health e Practices' website: https://healtheps.com/ Subscribe to our newsletter, Health e Connections: https://share.hsforms.com/1FMup6xLPSpeA8hB77caYQwd32sx?hsCtaAttrib=171926995377 Want more formal learning? Check out Jill's newly released course: Physician's Edge: Mastering Business & Finance in Your Medical Practice. 32.5 hours of online, on-demand CME-accredited training tailored just for busy physicians. Promo pricing available now: https://education.healtheps.com/offers/Ry3zfLYp/checkout?coupon_code=PHYSEDGE3000 Purchase your copy of Jill's book here: Physician Heal Thy Financial Self Join our Medical Money Matters Facebook Group here: https://www.facebook.com/groups/3834886643404507/ Original Musical Score by: Craig Addy at https://www.underthepiano.ca/ Visit Craig's website to book your Once in a Lifetime music experience Podcast coaching and development by: Jennifer Furlong, CEO, Communication Twenty-Four Seven https://www.communicationtwentyfourseven.com/    

Près de 250 morts et plus de 1100 cas recensés : le virus Ebola est toujours actif dans l'est de la RDC. Il n'y a pour l'instant ni vaccin ni traitement miracle mais parfois la maladie recule… Ca été le cas récemment à Bunia. « Au Centre médical évangélique, relate Le Journal de Kinshasa, l'air était plus léger dimanche. Plus chaud. Presque électrique. Devant une petite assemblée de journalistes venus en silence, quatre hommes et une femme s'avancent, sourire aux lèvres, regard fier. Ils ne sont plus des malades. Ils sont des survivants. Quatre nouveaux patients soignés pour Ebola viennent d'être déclarés guéris. Un cinquième l'avait été un peu plus tôt. En tout, se félicite le site congolais, cinq vies arrachées à la maladie, là où l'ombre du virus plane encore. Tous partagent un même destin : ils sont infirmiers. Et tous ont été contaminés… en sauvant des vies. Le docteur Calvin Ambitapio, directeur médical du CME, ne cache pas son émotion. Devant les micros, il livre un témoignage rare, presque inattendu : "nous sommes très contents de voir qu'une maladie qui n'a ni traitement propre, ni vaccin pour le moment, peut être vaincue par un traitement symptomatique". Alors, s'interroge Le Journal de Kinshasa, quel est ce protocole qui redonne espoir ? Une approche simple, mais rigoureuse : prise en charge du paludisme, antibiothérapie adaptée, surveillance quotidienne, prélèvements répétés. Pas de molécule miracle. Du soin. De l'attention. De l'acharnement thérapeutique. Résultat : après plusieurs jours d'observation, les tests sont tombés. Un par un. Négatifs ». Convaincre les populations Pour Afrik.com, « ces guérisons dépassent le seul cadre médical. La riposte contre Ebola se joue aussi dans la capacité à convaincre les populations que le soin peut sauver. Ces infirmiers rétablis à Bunia sont désormais la preuve vivante qu'un diagnostic précoce et une prise en charge adaptée peuvent augmenter considérablement les chances de survie. Leur guérison contredit l'idée, encore présente dans certaines localités touchées, selon laquelle l'entrée dans un centre de traitement équivaut à une condamnation. Dans cette bataille, la confiance devient donc un outil à part entière, relève encore Afrik.com. Sans adhésion des habitants, les protocoles médicaux les plus solides peuvent se heurter à la peur, aux soupçons et aux refus de prise en charge ». Pour sa part, le gouvernement congolais « affiche un optimisme prudent », relève La Tempête des Tropiques. « Le ministre de la Santé, Samuel Roger Kamba Mulamba, a estimé que la maladie pourrait être maîtrisée dans un délai de quatre à six mois grâce au renforcement de la riposte, à l'engagement communautaire et au soutien des partenaires internationaux ». La baisse des aides : une faute morale… Reste que « l'est de la RDC n'a pas seulement besoin d'interventions d'urgence, mais d'un engagement durable » : c'est ce qu'affirme dans une tribune publiée par Le Monde Afrique le médecin épidémiologiste humanitaire Didier Cannet. « Dans de nombreuses zones de l'Est congolais, l'État ne parvient plus à assurer ses fonctions essentielles, dit-il : sécurité, santé, éducation, infrastructures et protection des civils. Les systèmes de santé survivent grâce aux ONG internationales et aux financements extérieurs. Depuis plusieurs mois, la réduction de l'aide publique au développement et la baisse de certains financements américains, notamment par le biais de l'Usaid, l'Agence américaine pour le développement international, fragilisent encore davantage un système déjà au bord de la rupture. Cette situation constitue non seulement une faute morale, s'exclame le docteur Didier Cannet, mais aussi une erreur stratégique majeure, car les épidémies qui émergent dans l'est de la RDC ne resteront pas confinées indéfiniment dans les camps de déplacés de Goma ou dans les territoires isolés de l'Ituri ». Mauvais calcul… En effet, renchérit Jeune Afrique, en démantelant l'Usaid, l'administration Trump a fait un « mauvais calcul. (…) La prochaine pandémie coûtera probablement beaucoup plus cher que les milliards économisés aujourd'hui sur l'aide internationale. L'épidémie d'Ebola en RDC en donne déjà un aperçu ». Alors, certes, poursuit le site panafricain, « l'Afrique ne peut éternellement dépendre de Washington, de Bruxelles ou de Genève pour financer sa sécurité sanitaire. Elle doit encore bâtir des systèmes de santé plus solides, mieux financés et capables de répondre rapidement aux éventuelles menaces. Or, on en est loin. Mais prétendre que cette transition peut se faire alors que les financements internationaux ont été coupés net, c'est comme démonter des digues en arguant que la tempête n'a pas encore éclaté ».

Anthropic reicht das Börsenprospekt ein. Pip erklärt, warum Anthropic unbedingt vor OpenAI rausgehen muss. In Lenny Rachitskys Umfrage unter Tech-Profis ist Anthropic mit Abstand der Lieblings-Arbeitgeber. Google macht eine Kapitalerhöhung über $80 Mrd. statt wie üblich Aktien zurückzukaufen. Nvidia-CEO Jensen Huang sagt mit einer einzigen Aussage die SaaSocalypse ab und schickt Software-Aktien auf eine Rally. Nvidia greift mit RTX Spark Intel und AMD im PC-Markt an. Die Chicago Mercantile Exchange launcht AI-Token-Futures wie für Gold und Öl. Short-Seller Andrew Left wird wegen Marktmanipulation verurteilt. Bloomberg deckt auf, wie der SpaceX-IPO die S&P-500-Regeln zur Profitabilität aushebelt. Antonio Gracias wird durch den IPO zum Milliardär, sein Off-Balance-Sheet-Konstrukt mit SpaceX wird zum Streitthema. US Space Force vergibt $4,16 Mrd. an SpaceX für den Golden Dome. Instagram-Accounts werden gehackt, indem Hacker einfach Meta AI fragen. Salesforce kauft das Berliner Startup Contentful und hält selbst inzwischen einen $5-Mrd.-Anteil an Anthropic. Anthropic gibt der EU-Cybersecurity-Agentur ENISA Zugang zu Mythos. Unterstütze unseren Podcast und entdecke die Angebote unserer Werbepartner auf ⁠⁠⁠⁠⁠⁠doppelgaenger.io/werbung⁠⁠⁠⁠⁠⁠. Vielen Dank!  Philipp Glöckler und Philipp Klöckner sprechen heute über: (00:00:00) Anthropic reicht IPO-Prospekt ein (00:18:14) Anthropic ist Lieblings-Arbeitgeber (00:20:17) Google macht $80-Mrd.-Kapitalerhöhung (00:27:04) Jensen Huang sagt SaaSocalypse ab (00:33:47) Nvidia RTX Spark gegen Intel/AMD (00:39:46) AI-Token-Futures an der CME (00:43:06) MiniMax M3: China-Modell für 5-10% des Preises (00:46:01) HPE (00:47:13) Peter Thiel zieht nach Argentinien (00:49:32) SpaceX-Skeptiker: Musk vs. eigenes IPO-Filing (00:55:25) SpaceX-IPO biegt S&P-500-Regeln (00:59:29) Antonio Gracias und SpaceX' Off-Balance-Sheet-Konstrukt (01:07:28) US Space Force vergibt $4,16 Mrd. an SpaceX (01:09:15) Instagram-Hack via Meta AI (01:13:24) Salesforce kauft Berliner Contentful (01:18:17) Anthropic gibt EU/ENISA Zugang zu Mythos (01:19:33) Salesforces Anthropic-Stake auf $5 Mrd. Shownotes Anthropic-Ankündigung - xcancel.com Lenny Rachitsky: Ergebnisse einer Umfrage zu AI-Tools - linkedin.com Alphabet - ft.com Nvidia RTX Spark N1/N1X: AI-CPU/GPU für Laptops und Desktops - theverge.com Nvidia-CEO Jensen Huang zerstreut SaaSocalypse-Sorgen - wsj.com AI-Token-Futures kommen wie Gold und Öl - techcrunch.com MiniMax M3: Schlägt GPT-5.5 und Gemini 3.1 Pro bei 5-10% der Kosten - venturebeat.com HPE shares soar 37% - ft.com NYT: Warum Peter Thiel sich auf ein Leben nach Amerika vorbereitet (Argentinien) - nytimes.com SpaceX-Skeptiker: Musks Aussagen weichen vom IPO-Filing ab - cnbc.com Short-Seller Andrew Left wegen Wertpapierbetrug verurteilt - bloomberg.com SpaceX-IPO zwingt Indexfonds und Retail, die Regeln zu ändern - bloomberg.com Hedgeye-Tweet zu SpaceX/Markt - xcancel.com Fortune: SpaceX-IPO macht Musks Freund Antonio Gracias zum Milliardär - fortune.com US Space Force vergibt $4,16-Mrd.-Vertrag an SpaceX - reuters.com Coinbase und Kalshi launchen regulierte Perpetual-Krypto-Futures - reuters.com Hacker bekommen Zugang zu High-Profile-Instagram-Accounts durch Meta AI - 404media.co Gergely Orosz Tweet - xcancel.com Jane Wong Tweet - xcancel.com Salesforce übernimmt Berliner Startup Contentful - manager-magazin.de Salesforce kauft Contentful: Headless CMS für Agentforce - thenextweb.com Anthropic gibt EU-Cybersecurity-Agentur Zugang zu Mythos - bloomberg.com Salesforces Anthropic-Investment auf rund $5 Mrd. bewertet - bloomberg.com

Malignant Bowel Obstruction, VTE and Goals of CareMaster malignant bowel obstruction, cancer-associated thrombosis, and goals-of-care conversations in hospitalized patients with advanced cancer. Learn practical approaches to symptom management, anticoagulation decisions, and navigating high-stakes discussions around prognosis and hospice care. We're joined by  Dr. Jensa Morris, @JensaMorrisMD (Yale School of Medicine).Claim free CME for this episode at curbsiders.vcuhealth.org!Show Segments Intro Picks of the Week Case 1: Malignant small bowel obstruction: definitions, initial management, medications, NG tubes, nutrition, and procedural options Case 2: Cancer-associated VTE: choice of anticoagulant, treatment duration, unusual thromboses, and anticoagulation with brain metastases  Case 3: Goals of care: prognosis, performance status, palliative care, hospice and end-of-life planningTake Home Points Outro  Credits Writer, producer, and show notes: Reaford Blackburn, Jr., MD Infographic, Cover Art: Caroline Coleman, MD Hosts: Monee Amin, MD and Meredith Trubitt, MD    Reviewer: Rahul Ganatra, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Jensa Morris, MD Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.  Sponsor: LocumstoryLocumstory.com is literally just a free, unbiased resource dedicated to educating physicians about locums.Sponsor: Mint MobileTo get your new wireless plan for just 15 bucks a month, go to mintmobile.com/CURB. 

In this episode, Drs. Jason Silverman and Amber Hildreth talk to Dr. Valeria Cohran about the advances in intestinal rehabilitation care for infants and children with short bowel syndrome including changes nutrition management, line care and use of GLP-2 analogues that have led to decreases in intestinal failure associated liver disease and transplantation. Learning objectivesTo understand the composition and impact of multidisciplinary intestinal rehabilitation teams.To review the historical presentation of intestinal failure-associated liver disease (IFALD) and changes in practice that have reduced its prevalence and severity.To review GLP-2 analogues and their impact on outcomes and quality of life for children with short bowel syndrome. LinksPapers mentioned:PIFCON data paper on IFALDCholestasis and infection in long-term PNManagement of CVL in SBS Position PaperIntestinal Rehabilitation Teams Practice GuidelinePrevious episodes mentioned:Sue Protheroe - Enteral Nutrition in Intestinal FailureDanielle Wendel - Central Line Management in Intestinal Failure (Special JPGN Episode)Ruben Quiros-Tejeira - Multivisceral TransplantationPaul Wales - Surgical Management in Short Bowel SyndromeValeria Cohran & Conrad Cole - Racism in MedicineSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

In this episode, Tracey Davidoff, MD, Joe Toscano, MD, and Evan Nelson, MD, discuss the May 2026 Evidence-Based Urgent Care article, Urgent Care Evaluation and Management of Acute Bronchitis.0:08 Introduction1:08 Topic & guest introduction2:14 Differential diagnosis4:03 Respiratory virus testing6:42 Positive viral diagnosis & antibiotic prescribing8:00 Duration of cough & post-infectious cough9:41 Antibiotic stewardship12:07 Cough & cold medicines14:44 Narcotics & corticosteroids16:05 Steroid stewardship17:24 Radiologic stewardship & chest X-rays20:46 Sputum color21:53 Albuterol24:21 Special populations25:37 Take-home points & patient education27:08 Wrap-up and outroSubscribes, take the CME test here!Not a subscriber? Join here!

Listen in as our expert panel unpacks updated definitions of complicated vs. uncomplicated urinary tract infections, navigates antibiotic selection and duration, and shares the latest evidence-based strategies to stop recurrent UTIs in their tracks.Special guests:Dana Bowers, PharmD, BCPS, BCIDPAssociate ProfessorWashington State UniversityAkshith Dass, PharmD, MPH, BCPS, BCIDPAssistant Professor of Pharmacy PracticeNortheast Ohio Medical UniversityPharmacy Clinical Specialist Cleveland Clinic Mercy HospitalYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Craig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in April 2026.

Bitcoin just cratered to a six week low below $73,000 as fresh U.S. airstrikes on Iran reignited Strait of Hormuz war fears, triggering $897 million in long liquidations and the second largest daily IBIT outflow on record at $528 million. The pain is everywhere right now. Fund manager Michael Kramer is warning a $150 billion Treasury liquidity drain over the next week could send BTC much lower, while CME finally killed the famous weekend gap by launching 24/7 futures trading. Meanwhile, Iran is calling negotiations a strategic deadlock, the CFTC made a stunning admission that the Gemini case never should have been filed, the FBI just seized a record $8 billion in Bitcoin from a Cambodian scam compound, and Paxos became the first blockchain native firm approved by the SEC to clear and settle U.S. securities on chain. Plus a single enterprise client racked up a $500 million Claude bill in 30 days with no usage limits. We are breaking down whether Bitcoin defends $72K or rolls over to new lows, what the Hormuz escalation means for risk assets, and why this could be the most consequential 24 hours of the entire cycle. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, the crew discusses Bitcoin's current consolidation and MicroStrategy's recent wallet movements, while debating whether we're in a prolonged bear phase or setting up for the next leg up. Key highlights include the NYSE CEO calling Hyperliquid bigger than NASDAQ, CFTC approvals for the first regulated Bitcoin perps on Kalshi and Coinbase's Deribit access, CME launching 24/7 crypto futures, and Paxos winning SEC approval for on-chain U.S. stock settlement. The conversation also covers AI's impact on markets, liquidity rotation into big IPOs like SpaceX, altcoin consolidation, and the long-term fusion of crypto with traditional finance. Bullish developments vs. near-term caution — a must-listen Friday roundup. Learn more about your ad choices. Visit megaphone.fm/adchoices

Lavon Medlock has spent over two decades enhancing leaders' skills in problem-solving and coaching. Skilled in a variety of continuous improvement methods, she has trained leaders in creating effective daily management systems, deployed an integrated facility design approach to new construction projects like a 90,000-square-foot patient tower, and enhanced operations across different sectors.With a primary focus on the healthcare industry, Lavon has worked with clinical leaders to combine the Institute of Healthcare Improvement's teachings on quality with A3 thinking and key project management principles. She's a practitioner, teacher, and coach in the field of A3 thinking and holds certifications in both Project Management (PMI-PMP) and Six Sigma Green Belt.In addition to instructing and coaching for the Lean Enterprise Institute, she teaches graduate coursework at The Ohio State University. Her educational background includes a Bachelor of Science in Public Health from the University of North Carolina at Chapel Hill and a Master of Science in Healthcare Administration from Oregon Health & Science University.Link to claim CME credit: https://www.surveymonkey.com/r/3DXCFW3CME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

Hosts: Jake Lancaster MD, Chief Medical Information Officer and Amanda Comer DNP, System Director, Advanced Practice ProvidersDr. Stephen Threlkeld, Baptist Memorial Health Care's medical director of infectious diseases, contributed to a case study published on Thursday, Jan. 8, 2026, in the prestigious New England Journal of Medicine titled “Case 1-2026: A 50-Year-Old Woman With Fever and Abdominal Pain.”The case study, published in Vol. 394, No. 2 of the journal, is part of a century-old series called “Case Records of the Massachusetts General Hospital.” It explores clinical cases that challenge physicians.CME Credit Info:Link to complete brief survey and claim CME credit: https://www.surveymonkey.com/r/C55LKSYCME credit is available for up to 3 years after the stated release dateContact CEOD@bmhcc.org if you have any questions about claiming credit.

With an abundance of therapeutic options for managing diabetic macular edema (DME), what patient characteristics inform your treatment decisions? Does the number of loading doses influence long-term macular fluid outcomes? How are you managing insurance-mandated step-therapy in your patients? In today's episode, host Dr. Jay Sridhar invites Drs. Durga Borkar and Carl Danzig to share how they've integrated new anti-VEGF therapies into clinical practice. For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Arvind Dasari, MD, MS CME information and select publications

Proceedings from a webinar on April 16, 2026, moderated by Dr Neil Love, including the following topics: Introduction: Research To Practice Paper of the Year! (0:00) Checkpoint Inhibitors for Localized Microsatellite Instability-High Tumors (11:12) Circulating Tumor DNA Assays (21:58) Checkpoint Inhibitors for Metastatic Disease (38:32) CME information and select publications

In this Unfiltered episode of Fixing Healthcare, Drs. Robert Pearl and Jonathan Fisher explore three questions that reach across medicine, leadership and life itself: What legacy do physicians leave behind? How does mindset shape health and longevity? And can doctors still find fulfillment as medical practice shifts from independence to employment? The conversation begins with Tim Cook's legacy at Apple, using his tenure as CEO to ask a larger question about values, mission and compromise. Pearl and Fisher examine whether legacy is something others assign after a career ends or something professionals create daily through their choices, actions and alignment with their deepest values. For physicians, the question becomes especially personal when financial, organizational or career decisions collide with the promise to put patients first. Midway through, the discussion turns to longevity and the science of mindset. Drawing on research from Yale and Fisher's work in Just One Heart, the two physicians explore how beliefs about aging can influence physical function, cognitive health, inflammation and long-term well-being. Fisher explains why optimism is not merely a pleasant attitude but a physiologic force that can shape stress hormones, inflammatory pathways and the daily behaviors that determine health. Finally, Pearl and Fisher examine one of the biggest structural shifts in modern medicine: the movement from physician-owned practices to employment by hospitals, health systems and insurers. Fisher notes that independent doctors may report lower burnout, but autonomy is no longer guaranteed when administrative burdens, call schedules and financial pressures consume the practice of medicine. Employment offers support and stability, but often at the cost of control. By the end, the episode connects all three themes: legacy, health and professional fulfillment are rooted in purpose. Whether through family, patient care, mission trips, mentoring or the daily work of medicine, Pearl and Fisher suggest that doctors may live longer, healthier and more meaningful lives when they preserve the mission that brought them to medicine in the first place. For listeners who connected with Fisher's reflections on burnout, autonomy and the search for renewed purpose in medicine, his upcoming ASPIRE physician retreat offers a deeper opportunity for reflection and recovery. Co-facilitated with Dr. Robyn Tiger, ASPIRE is a CME-accredited retreat designed exclusively for healthcare professionals, taking place June 12-14 at the Art of Living Retreat Center in Boone, North Carolina. Use code ASPIRE15 for 15% off registration. For more unfiltered conversation, listen to the full episode and explore these related resources: ‘Just One Heart' (Jonathan Fisher's newest book) ‘ChatGPT, MD' (Robert Pearl's newest book) Monthly Musings on American Healthcare (Robert Pearl's newsletter) * * * Fixing Healthcare is a co-production of Dr. Robert Pearl and Jeremy Corr. Subscribe to the show via Apple Podcasts, Spotify or wherever you find podcasts. Join the conversation or suggest a guest by following the show on X and LinkedIn. The post FHC #216: An unfiltered look at what legacy means in medicine appeared first on Fixing Healthcare.

Join us as we review recent articles and news featured in The DIGEST, including updated lipid guidelines, GLP1 agonists holds and procedures, the newest drug in pancreatic cancer, and discontinuing thyroid supplementation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Nora Taranto (@norataranto), Laura Glick (@lauraglick) and Matt Watto (@doctorwatto).Claim free CME for this episode at curbsiders.vcuhealth.org!Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME!Credits Written and Hosted by: Nora Taranto MD MSCE, Laura Glick MD,  Matthew Watto MD, FACP Cover Art:  Nora Taranto MD MSCE Reviewers: Emi Okamoto MD  Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro and pun   Lipid Management Guidelines Overview  Emerging Treatments in Oncology  Press Release on a new KRAS Inhibitor for Pancreatic Cancer  Perioperative Considerations for GLP-1 Use  Deprescribing Levothyroxine in Older Adults Sponsor: Panacea FinancialIf you're about to make the leap into  residency and feeling the financial pressure of that transition, visit  PanaceaFinancial.com/curbsiders today. Sponsor: UpToDatefor a limited time, get 10% off UpToDate packages with code CURB10. Visit store.uptodate.com to save on your annual or longer personal UpToDate subscription today. 

Rebecca from Jito Labs joins Haseeb, Tom, and Tarun for a regulation deep-dive covering the CLARITY Act's stablecoin yield compromise and presidential ethics sticking points, CME and ICE's lobbying war against Hyperliquid's RWA perps, the prediction market legal battle heading to the Supreme Court, and whether the SEC's tokenized securities innovation exemption will actually matter. Welcome to The Chopping Block – where crypto insiders Haseeb Qureshi, Tom Schmidt, Tarun Chitra, and Robert Leshner chop it up about the latest in crypto. This week, joining us is Rebecca Rettig, Chief Legal Officer at Jito Labs, who's here to help the crew make sense of the absolute regulatory tornado tearing through the industry. First up: the CLARITY Act. It just got out of Senate Banking Committee, but the road to passage is anything but smooth. The stablecoin yield fight with banks ended in a "do stuff yield" compromise, but presidential ethics provisions remain the last polarizing hurdle. Rebecca breaks down what actually changes for token founders if it passes — spoiler: not much immediately, since rulemaking alone could take years. Then: CME and ICE have declared war on Hyperliquid, lobbying the Hill to force CFTC registration on the decentralized perps giant. The crew debates who actually wins US regulated perps, whether Hyperliquid's pre-IPO markets represent a genuine threat to investment banking, and Rebecca introduces "on-chain finance" — a distinction the panel immediately roasts her for. Finally: prediction markets are in a legal bloodbath across state courts with a Supreme Court showdown likely by 2027, and the SEC's tokenized securities innovation exemption has Twitter buzzing but Rebecca skeptical. Let's get into it. Listen to the episode on Apple Podcasts, Spotify, Pods, Fountain, Podcast Addict, Pocket Casts, Amazon Music, or on your favorite podcast platform. Show highlights

Unpacking Hyperliquid's ATH with Michaël van de Poppe. In today's Markets Outlook, Michaël van de Poppe, Founder and CIO of MN Capital and MN Fund, joins CoinDesk's Jennifer Sanasie to share why Hyperliquid is hitting new all-time highs. He makes the case for NEAR and Bittensor as undervalued AI crypto plays compared to overhyped tech IPOs, and explains why he's steering clear of privacy coins like Zcash. Plus, his key macro signals to watch over the next four to six weeks. - Timecodes: 00:00 - What Michaël Is Watching in the Markets? 01:47 - Why European Traders Are Flocking to Hyperliquid 02:59 - HYPE Price Target & HYPE vs. Solana 05:09 - Responding to CME, ICE Regulatory Scrutiny of HYPE 07:27 - Are Altcoins Dead? 08:59 - The Case for NEAR Over AI IPOs 10:43 - Why Bittensor Could Reach $1,000-$2,000 12:48 - Privacy and Zcash 16:33 - Macro Outlook: Yields, the Fed, and What's Next - This episode was hosted by Jennifer Sanasie.